Evidence map›Paper›PMID 26374448›Full record

Trial reportInternational journal of obesity (2005)2016

Differential effects of leptin on adiponectin expression with weight gain versus obesity.

P Singh, P Sharma, K R Sahakyan, D E Davison, F H Sert-Kuniyoshi, A Romero-Corral, J M Swain, M D Jensen, F Lopez-Jimenez, T Kara and 1 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of obesity (2005), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Periconceptional biomarkers for maternal obesity: a systematic review.Reviews in endocrine & metabolic disorders · 2023
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

P SinghDivision of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
P SharmaDivision of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
K R SahakyanDivision of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
D E DavisonDivision of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
F H Sert-KuniyoshiDivision of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
A Romero-CorralDivision of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
J M SwainDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.
M D JensenEndocrinology Research Unit, Mayo Clinic, Rochester, MN, USA.
F Lopez-JimenezDivision of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
T KaraDivision of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
V K SomersDivision of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · USUniversity Hospital Brno · CZUniversity of Arizona · USWinnMed · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
REGIONAL FATTY ACID METABOLISM IN HUMANSR01DK045343 · NIDDK · MAYO CLINIC ROCHESTER · PI MICHAEL D. JENSEN · 1992 to 2026
$12.9M
Disease Mechanisms in Sleep ApneaR01HL065176 · NHLBI · MAYO CLINIC ROCHESTER · PI SOMERS, VIREND K · 1999 to 2021
$5.8M
Fat Gain and Cardiovascular Disease MechanismsR01HL073211 · NHLBI · MAYO CLINIC ROCHESTER · PI SOMERS, VIREND K · 2003 to 2007
$1.8M
Molecular Mechanisms Mediating Resistance to Leptin Signaling During Fat GainR21DK081014 · NIDDK · MAYO CLINIC ROCHESTER · PI SOMERS, VIREND K · 2008 to 2009
$416k
NCATS NIH HHS 1UL1 TR000135NCATS NIH HHS UL1 TR000135NHLBI NIH HHS HL65176NHLBI NIH HHS HL73211NHLBI NIH HHS R01 HL065176NHLBI NIH HHS R01 HL073211NIDDK NIH HHS DK45343NIDDK NIH HHS DK81014NIDDK NIH HHS R01 DK045343NIDDK NIH HHS R21 DK081014
6 · The paper itself

Abstract

BACKGROUND/

objectiveAdiponectin exerts beneficial effects by reducing inflammation and improving lipid metabolism and insulin sensitivity. Although the adiponectin level is lower in obese individuals, whether weight gain reduces adiponectin expression in humans is controversial. We sought to investigate the role of weight gain, and consequent changes in leptin, on altering adiponectin expression in humans. METHODS/

resultsForty-four normal-weight healthy subjects were recruited (mean age 29 years; 14 women) and randomized to either gain 5% of body weight by 8 weeks of overfeeding (n=34) or maintain weight (n=10). Modest weight gain of 3.8±1.2 kg resulted in increased adiponectin level (P=0.03), whereas weight maintenance resulted in no changes in adiponectin. Further, changes in adiponectin correlated positively with changes in leptin (P=0.0085). In-vitro experiments using differentiated human white preadipocytes showed that leptin increased adiponectin mRNA and protein expression, whereas a leptin antagonist had opposite effects. To understand the role of leptin in established obesity, we compared adipose tissue samples obtained from normal-weight versus obese subjects. We noted, first, that leptin activated cellular signaling pathways and increased adiponectin mRNA in the adipose tissue from normal-weight participants, but did not do so in the adipose tissue from obese participants. Second, we noted that obese subjects had increased caveolin-1 expression, which attenuates leptin-dependent increases in adiponectin.

conclusionsModest weight gain in healthy individuals is associated with increases in adiponectin levels, which correlate positively with changes in leptin. In vitro, leptin induces adiponectin expression, which is attenuated by increased caveolin-1 expression. In addition, the adipose tissue from obese subjects shows increased caveolin-1 expression and impaired leptin signaling. This leptin signal impairment may prevent concordant increases in adiponectin levels in obese subjects despite their high levels of leptin. Therefore, impaired leptin signaling may contribute to low adiponectin expression in obesity and may provide a target for increasing adiponectin expression, hence improving insulin sensitivity and cardio-metabolic profile in obesity.

Indexed as

ObesityWeight GainAdiponectinAdipose TissueAgingBody Mass IndexCaveolin 1FemaleHumansLeptinLipid MetabolismLongitudinal StudiesMalePrevalenceSignal TransductionUnited StatesAdiponectinADIPOQ protein, humanCAV1 protein, humanCaveolin 1Leptin

Identifiers

PMID26374448
PMCPMC4747836
OpenAlexW2277571790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.